A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2017
Price : $35 *
At a glance
- Drugs SCT 200 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Sinocelltech
- 08 Apr 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.
- 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to active, no longer recruiting.
- 13 Aug 2014 New trial record